PharmTech Drug Digest 11.20
News|Articles|April 8, 2015

Avomeen Announces New President

Avomeen Analytical Services announces that David W. Riggs, PE will take the role of president of the company.

 

Avomeen Analytical Services announced on April 7, 2015 that it would appoint David W. Riggs as president of the company. Riggs will join Avomeen with almost 30 years of experience in advanced analytical chemistry, product development, chemical engineering, and other roles within the industry.

“David brings excellent credentials into our growing laboratory; his dedication to building successful relationships with clients through long-term mutually beneficial business partnerships is to be admired.  He has the vision and ambition to take Avomeen to the next level and comes highly recommended from within the industry.  David brings to Avomeen his experience with sales integrations, acquisitions, and the launch of new testing opportunities,” said Shri Thanedar, PhD, CEO of Avomeen Analytical Services, in a press release.

Avomeen is a full-service chemical testing laboratory with product testing and formulation development services. The company specializes in deformulation analysis (reverse engineering), product development, stability testing, pharmaceutical research and development, litigation support services, and pharmaceutical product lifecycle support.

Source: Avomeen


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.